Literature DB >> 26269537

Correlates of Vaccine-Induced Protection against Mycobacterium tuberculosis Revealed in Comparative Analyses of Lymphocyte Populations.

Sherry L Kurtz1, Karen L Elkins2.   

Abstract

A critical hindrance to the development of a novel vaccine against Mycobacterium tuberculosis is a lack of understanding of protective correlates of immunity and of host factors involved in a successful adaptive immune response. Studies from our group and others have used a mouse-based in vitro model system to assess correlates of protection. Here, using this coculture system and a panel of whole-cell vaccines with varied efficacy, we developed a comprehensive approach to understand correlates of protection. We compared the gene and protein expression profiles of vaccine-generated immune peripheral blood lymphocytes (PBLs) to the profiles found in immune splenocytes. PBLs not only represent a clinically relevant cell population, but comparing the expression in these populations gave insight into compartmentally specific mechanisms of protection. Additionally, we performed a direct comparison of host responses induced when immune cells were cocultured with either the vaccine strain Mycobacterium bovis BCG or virulent M. tuberculosis. These comparisons revealed host-specific and bacterium-specific factors involved in protection against virulent M. tuberculosis. Most significantly, we identified a set of 13 core molecules induced in the most protective vaccines under all of the conditions tested. Further validation of this panel of mediators as a predictor of vaccine efficacy will facilitate vaccine development, and determining how each promotes adaptive immunity will advance our understanding of antimycobacterial immune responses.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26269537      PMCID: PMC4580742          DOI: 10.1128/CVI.00301-15

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  81 in total

1.  The Achilles heel of BCG.

Authors:  Ian M Orme
Journal:  Tuberculosis (Edinb)       Date:  2010-07-24       Impact factor: 3.131

2.  Measurement of macrophage-mediated killing of intracellular bacteria, including Francisella and mycobacteria.

Authors:  Karen L Elkins; Siobhán C Cowley; J Wayne Conlan
Journal:  Curr Protoc Immunol       Date:  2011-04

3.  Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

Authors:  R Maini; E W St Clair; F Breedveld; D Furst; J Kalden; M Weisman; J Smolen; P Emery; G Harriman; M Feldmann; P Lipsky
Journal:  Lancet       Date:  1999-12-04       Impact factor: 79.321

4.  Dose of BCG does not influence the efficient generation of protective immunity in mice challenged with Mycobacterium tuberculosis.

Authors:  V Gruppo; I M Orme
Journal:  Tuberculosis (Edinb)       Date:  2002       Impact factor: 3.131

5.  Identification of nitric oxide synthase as a protective locus against tuberculosis.

Authors:  J D MacMicking; R J North; R LaCourse; J S Mudgett; S K Shah; C F Nathan
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-13       Impact factor: 11.205

6.  Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice.

Authors:  J L Flynn; M M Goldstein; J Chan; K J Triebold; K Pfeffer; C J Lowenstein; R Schreiber; T W Mak; B R Bloom
Journal:  Immunity       Date:  1995-06       Impact factor: 31.745

7.  Involvement of cytokines in determining resistance and acquired immunity in murine tuberculosis.

Authors:  M Denis
Journal:  J Leukoc Biol       Date:  1991-11       Impact factor: 4.962

8.  CD4-CD8- T cells control intracellular bacterial infections both in vitro and in vivo.

Authors:  Siobhán C Cowley; Elizabeth Hamilton; Jeffrey A Frelinger; Jie Su; James Forman; Karen L Elkins
Journal:  J Exp Med       Date:  2005-07-18       Impact factor: 14.307

9.  Inhibition of mycobacterial growth in vitro following primary but not secondary vaccination with Mycobacterium bovis BCG.

Authors:  Helen A Fletcher; Rachel Tanner; Robert S Wallis; Joel Meyer; Zita-Rose Manjaly; Stephanie Harris; Iman Satti; Richard F Silver; Dan Hoft; Beate Kampmann; K Barry Walker; Hazel M Dockrell; Uli Fruth; Lew Barker; Michael J Brennan; Helen McShane
Journal:  Clin Vaccine Immunol       Date:  2013-08-28

10.  Levels of soluble VCAM-1, soluble ICAM-1, and soluble E-selectin in patients with tuberculous pleuritis.

Authors:  A Hamzaoui; K Hamzaoui; A Kahan; A Chabbou
Journal:  Mediators Inflamm       Date:  1996       Impact factor: 4.711

View more
  7 in total

Review 1.  The Many Hosts of Mycobacteria 8 (MHM8): A conference report.

Authors:  Michelle H Larsen; Karen Lacourciere; Tina M Parker; Alison Kraigsley; Jacqueline M Achkar; Linda B Adams; Kathryn M Dupnik; Luanne Hall-Stoodley; Travis Hartman; Carly Kanipe; Sherry L Kurtz; Michele A Miller; Liliana C M Salvador; John S Spencer; Richard T Robinson
Journal:  Tuberculosis (Edinb)       Date:  2020-02-11       Impact factor: 3.131

2.  Activities of Murine Peripheral Blood Lymphocytes Provide Immune Correlates That Predict Francisella tularensis Vaccine Efficacy.

Authors:  Roberto De Pascalis; Lara Mittereder; Nikki J Kennett; Karen L Elkins
Journal:  Infect Immun       Date:  2016-03-24       Impact factor: 3.441

3.  A panel of correlates predicts vaccine-induced protection of rats against respiratory challenge with virulent Francisella tularensis.

Authors:  Roberto De Pascalis; Andrew Hahn; Helen M Brook; Patrik Ryden; Nathaniel Donart; Lara Mittereder; Blake Frey; Terry H Wu; Karen L Elkins
Journal:  PLoS One       Date:  2018-05-25       Impact factor: 3.240

4.  Working correlates of protection predict SchuS4-derived-vaccine candidates with improved efficacy against an intracellular bacterium, Francisella tularensis.

Authors:  Roberto De Pascalis; Blake Frey; Helen M Rice; Varunika Bhargava; Terry H Wu; Ross L Peterson; J Wayne Conlan; Anders Sjöstedt; Karen L Elkins
Journal:  NPJ Vaccines       Date:  2022-08-17       Impact factor: 9.399

Review 5.  Bacterial Vaccine Antigen Discovery in the Reverse Vaccinology 2.0 Era: Progress and Challenges.

Authors:  Fadil A Bidmos; Sara Siris; Camilla A Gladstone; Paul R Langford
Journal:  Front Immunol       Date:  2018-10-08       Impact factor: 7.561

6.  The Diversity Outbred Mouse Population Is an Improved Animal Model of Vaccination against Tuberculosis That Reflects Heterogeneity of Protection.

Authors:  Sherry L Kurtz; Amy P Rossi; Gillian L Beamer; Dan M Gatti; Igor Kramnik; Karen L Elkins
Journal:  mSphere       Date:  2020-04-15       Impact factor: 4.389

7.  Immune lymphocytes halt replication of Francisella tularensis LVS within the cytoplasm of infected macrophages.

Authors:  Mary Katherine Bradford; Karen L Elkins
Journal:  Sci Rep       Date:  2020-07-21       Impact factor: 4.996

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.